他汀类药物与非肝硬化慢性肝病患者严重肝病风险降低相关
基于瑞典全国性队列的肝组织病理学数据,纳入3862例有他汀暴露的非肝硬化慢性肝病患者,并与3862例无他汀暴露者进行1:1匹配及倾向性评分匹配。他汀使用与严重肝病风险降低相关(HR 0.60,95%CI 0.48-0.74),在酒精相关肝病和非酒精性脂肪性肝病中观察到统计学显著降低,但在病毒性肝炎和自身免疫性肝炎中未达统计学显著。
要点
- 他汀使用者严重肝病发生率为6.1%(234例),非使用者为7.1%(276例),HR 0.60(95%CI 0.48-0.74)。
- 酒精相关肝病中他汀使用与严重肝病风险降低相关(HR 0.30,95%CI 0.19-0.49),非酒精性脂肪性肝病中HR 0.68(95%CI 0.45-1.00)。
- 他汀使用与肝硬化进展(HR 0.62,95%CI 0.49-0.78)、肝细胞癌(HR 0.44,95%CI 0.27-0.71)和肝相关死亡(HR 0.55,95%CI 0.36-0.82)风险降低相关。
核心结论
- 在非肝硬化慢性肝病患者中,他汀新使用与严重肝病发生率降低相关,提示其可能具有疾病修饰作用。
研究设计与样本
- 利用瑞典全国性队列的肝组织病理学数据,识别3862例有他汀暴露的非肝硬化慢性肝病患者。
- 他汀暴露定义为累计配取30个或以上限定日剂量的他汀处方。
- 他汀使用者与3862例无他汀暴露的慢性肝病患者通过直接1:1匹配后进行倾向性评分匹配。
- 采用Cox回归估计发生严重肝病(肝硬化、肝细胞癌和肝移植/肝相关死亡的复合终点)的风险比(HR)。
主要发现
- 慢性肝病患者中45.3%为非酒精性脂肪性肝病,21.9%为酒精相关肝病,17.7%为病毒性肝炎,15.1%为自身免疫性肝炎。
- 随访期间,他汀使用者中234例(6.1%)发生严重肝病,非使用者中276例(7.1%)发生严重肝病。
- 他汀使用与严重肝病风险降低相关(HR 0.60,95%CI 0.48-0.74)。
- 酒精相关肝病中他汀使用与严重肝病风险降低相关(HR 0.30,95%CI 0.19-0.49),非酒精性脂肪性肝病中HR 0.68(95%CI 0.45-1.00),病毒性肝炎中HR 0.76(95%CI 0.51-1.14),自身免疫性肝炎中HR 0.88(95%CI 0.48-1.58)。
- 他汀使用与肝硬化进展风险降低相关(HR 0.62,95%CI 0.49-0.78),与肝细胞癌风险降低相关(HR 0.44,95%CI 0.27-0.71),与肝相关死亡风险降低相关(HR 0.55,95%CI 0.36-0.82)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Little is known about the potential impact of statins on the progression of noncirrhotic chronic liver diseases (CLDs) to severe liver disease. METHODS: Using liver histopathology data in a nationwide Swedish cohort, we identified 3862 noncirrhotic individuals with CLD and statin exposure, defined as a statin prescription filled for 30 or more cumulative defined daily doses. Statin users were matched to 3862 (statin) nonusers with CLD through direct 1:1 matching followed by propensity score matching. Cox regression was used to estimate hazard ratios (HRs) for the primary outcome of incident severe liver disease (a composite of cirrhosis, hepatocellular carcinoma, and liver transplantation/liver-related mortality). RESULTS: A total of 45.3% of CLD patients had nonalcoholic fatty liver disease, 21.9% had alcohol-related liver disease, 17.7% had viral hepatitis, and 15.1% had autoimmune hepatitis. During follow-up evaluation, 234 (6.1%) statin users vs 276 (7.1%) nonusers developed severe liver disease. Statin use was associated with a decreased risk of developing severe liver disease (HR, 0.60; 95% CI, 0.48-0.74). Statistically significantly lower rates of severe liver disease were seen in alcohol-related liver disease (HR, 0.30; 95% CI, 0.19-0.49) and in nonalcoholic fatty liver disease (HR, 0.68; 95% CI, 0.45-1.00), but not in viral hepatitis (HR, 0.76; 95% CI, 0.51-1.14) or autoimmune hepatitis (HR, 0.88; 95% CI, 0.48-1.58). Statin use had a protective association in both prefibrosis and fibrosis stages at diagnosis. Statin use was associated with lower rates of progression to cirrhosis (HR, 0.62; 95% CI, 0.49-0.78), hepatocellular carcinoma (HR, 0.44; 95% CI, 0.27-0.71), and liver-related mortality (HR, 0.55; 95% CI, 0.36-0.82). CONCLUSIONS: Among individuals with noncirrhotic CLD, incident statin use was linked to lower rates of severe liver disease, suggesting a potential disease-modifying role.
引用
- Sharma R, Simon TG, Hagström H, et al. Statins Are Associated With a Decreased Risk of Severe Liver Disease in Individuals With Noncirrhotic Chronic Liver Disease. Clin Gastroenterol Hepatol. 2023. PMID: 37121528. doi:10.1016/j.cgh.2023.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。